Biomarkers Consortium
The Biomarkers Consortium brings together various partners to identify, develop and qualify potential biomarkers to improve drug development and regulatory decision-making.
Spotlight
Skip This SectionSpotlight
The FNIH announces promising new data for Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE)
Spotlight
FNIH highlights the success of the ABC-CT program in advancing neuropsychiatric biomarkers for autism.
Spotlight
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Spotlight
New Video–Vol-PACT: A Novel Cancer Imaging Project
Vision
Improving health through meaningful measurements.
Mission
To create and lead cross-sector efforts that validate and qualify biomarkers and other drug development tools to accelerate better decision making for the development of new therapeutics and health technologies.